The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.
Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.
Child depression at ages 10 and 11 years during the COVID-19 pandemic was significantly associated with later maternal depression, according to longitudinal study results.
Child depression at ages 10 and 11 years during the COVID-19 pandemic was significantly associated with later maternal depression, according to longitudinal study results.
Patients with attention-deficit/hyperactivity disorder (ADHD) who began drug treatment within 3 months of diagnosis had significantly reduced rates of suicidal behaviors, substance misuse, traffic accidents, and criminality.
Patients with attention-deficit/hyperactivity disorder (ADHD) who began drug treatment within 3 months of diagnosis had significantly reduced rates of suicidal behaviors, substance misuse, traffic accidents, and criminality.
An investigational prescription digital therapeutic targeting negative symptoms in patients with schizophrenia met its primary endpoint in a pivotal phase 3 randomized controlled study.
An investigational prescription digital therapeutic targeting negative symptoms in patients with schizophrenia met its primary endpoint in a pivotal phase 3 randomized controlled study.
Compared with older adults without insomnia, older adults with the sleep disorder experienced a 3-fold greater increase in depressed mood and depressive symptoms after exposure to an inflammatory challenge, according to study findings.
Compared with older adults without insomnia, older adults with the sleep disorder experienced a 3-fold greater increase in depressed mood and depressive symptoms after exposure to an inflammatory challenge, according to study findings.
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
Take this quick quiz to test your knowledge on combination treatment strategies, novel mechanisms, and how emerging data is reshaping care for complex patients of all ages.
Take this quick quiz to test your knowledge on combination treatment strategies, novel mechanisms, and how emerging data is reshaping care for complex patients of all ages.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.